KOGA Yoshikatsu, MD, PhD

Official Title

• Chief, Department of Strategic Programs, EPOC, National Cancer Center
• Head, Section of Experimental Animals, EPOC, National Cancer Center
• Head, Translational Research Sample Management Section, National Cancer Center Hospital East
• Research Scientist, Division of Developmental Therapeutics, EPOC, National Cancer Center

Area of research

• Tumor Diagnostics
• Tumor Therapeutics
• Oncology

Keywords

• Drug delivery system (DDS)
• Armed antibody
• PDX models
• Organoid models
• Perfusable organoid models
• Co-clinical trials
• Animal alternatives

Current main research theme

• Preclinical study of armed antibody (ADC, RIT, and PIT)
• Co-clinical trials of anticancer drugs
• Microphysiological system (MPS) and animal alternatives in development of anticancer drugs

Collaborative research themes

• Preclinical study of armed antibody
• PDX models and organoid models for development of co-clinical trials
• Development of a new MPS

Email

ykoga●east.ncc.go.jp（Replace ● to @）

Brief History

• 1993-1999  Kumamoto University, Medical School, MD
• 2003-2009  Kumamoto University Graduate School of Medicine, PhD
   
• 1999-2000  Kumamoto University Hospital, Resident
• 2000-2002  Miyazaki Prefectural Nobeoka Hospital, Surgeon
• 2002-2003  Minamata Medical Center Hospital, Surgeon
• 2003-2006  Kumamoto University Hospital, Surgeon
• 2006-2009  National Cancer Center Hospital East, Research Resident of Investigative Treatment Division
• 2009-2011  National Cancer Center Hospital East, Research Fellow of Division of Developmental Therapeutics
• 2011-         National Cancer Center, Section Head of Experimental Animals
• 2019-         National Cancer Center, Chief of Department of Strategic Programs
• 2021-         National Cancer Center Hospital East, Head of TR Sample Management Section
• 2021-2023  Tokyo Medical and Dental University, Visiting Associate Professor of Department of NCC Cancer Science

Qualifications

• National Board of Medicine
• Japanese Board of Surgery
• Japanese Board of Gastroenterology
• Japanese Board of Hepatology
• Japanese Board of Gastrointestinal Cancer Screening
• Biorepository Technical Administrator (BiTA)

 Major affiliated societies

• Japan Surgical Society
• Japanese Society of Gastroenterological Surgery
• Japanese Society of Gastroenterology
• Japan Society of Clinical Oncology
• Japan Society of Hepatology
• Japanese Cancer Association (Councilor)
• Japan Society of Drug Delivery System (Councilor/Member of Editorial Board)
• Japanese Society of Gastrointestinal Cancer Screening
• American Association for Cancer Research

Publications

1. Tsumura R, Koga Y, Hamada A, Kuwata T, Sasaki H, Doi T, Aikawa K, Ohashi A, Katano I, Ikarashi Y, Ito M, Ochiai A. The report of the use of patient-derived xenograft models in the development of anticancer drugs in Japan. Cancer Sci 111(9):3386-3394, 2020.
2. Koga Y, Ochiai A. Systematic Review of Patient-Derived Xenograft Models for Preclinical Studies of Anti-Cancer Drugs in Solid Tumors. Cells 8(5):418, 2019.
3. Yamazaki N, Koga Y, Taniguchi H, Kojima M, Kanemitsu Y, Saito N, Matsumura Y. High expression of miR-181c as a predictive marker of recurrence in stage II colorectal cancer. Oncotarget 8(4):6970-6983, 2017.
4. Koga Y, Manabe S, Aihara Y, Sato R, Tsumura R, Iwafuji H, Furuya F, Fuchigami H, Fujiwara Y, Hisada Y, Yamamoto Y, Yasunaga M, Matsumura Y. Antitumor effect of anti-tissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts. Int J Cancer 137(6):1457-1466, 2015.
5. Koga Y, Yasunaga M, Takahashi A, Kuroda J, Moriya Y, Akasu T, Fujita S, Yamamoto S, Baba H, Matsumura Y. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res 3(11):1435-1442, 2010.